Allogene Therapeutics, Inc.
ALLO · NASDAQ
Bulios Fair Price
$1.07
37.8% downside
Trenutna cena
$1.72
Po podatkih Bulios Fair Price je delnica ALLO trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Allogene Therapeutics, Inc. (ALLO) is a biotechnology company specializing in the development and commercialization of allogeneic (non-related) CAR-T cell therapies for the treatment of various types of cancer. The company focuses on utilizing genetically modified T cells that can selectively identify and eliminate tumor cells. Allogeneic therapies have the potential to transform the cancer treatment landscape and provide new opportunities for patients. With its research and development of innovative therapeutic approaches, investing in Allogene Therapeutics, Inc. (ALLO) shares may present an interesting investment opportunity for investors interested in the biotechnology and medical sector.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Zachary Roberts
Employees
151
Headquarters
South San Francisco
Prihajajoči dogodki
Earnings
Upcoming earnings report